SEC filing record
Primary Source · SEC.gov

4C Medical Technologies, Inc.

2025 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalStalledForm D/A · 2026-03-312 events: 1 stalled, 1 new form d filerLast filing 2026-03-31

Raised

$72M

Investors

80

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

4C Medical Technologies, Inc. is a Delaware corporation that first filed a Form D on December 14, 2016 and most recently amended it on March 31, 2026 in the Other Technology industry group. The offering claims Rule 506(b) and covers equity. 4C Medical Technologies, Inc. reported $71,608,160 sold from 80 investors of a $166,095,595 total offering as of the Form D filed March 31, 2026. The filing states that the figure is combined across related vehicles, so it is not this entity's figure alone. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Piper Sandler & Co. (CRD 665) as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $9,295,063 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 6655 Wedgwood Road North, Suite 160, Maple Grove, MN 55311.

Critical Disclosures

What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.

Offering stalled · Form D · last filing March 31, 2026

Latest annual amendment reported no change in amount sold or investors

Timeline
Each line is a fact as filed. The history behind it, the same event across other issuers, and an alert on the next one:Open in the terminal Watch this issuer

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001692028
Entity Name4C Medical Technologies, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address6655 Wedgwood Road North, Suite 160, Maple Grove, MN 55311
Phone(952) 334-4363
Industry / Fund TypeOther Technology
Securities TypeEquity
First Sale DateMarch 4, 2026
Filing DateMarch 31, 2026
Accession Number0001437749-26-010592
Total Offering Amount$166,095,595
Total Amount Sold$71,608,160
Amount Remaining$94,487,435
Amount Sold NoteCombined figure across related vehicles: 13(a) and (b) include the conversion of notes having an outstanding balance of $34,608,151. Excludes sales made to certain non-U.S. investors in reliance on Regulation S.
Total Investors80
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$9,295,063 (to Piper Sandler & Co.)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)MN
Amendment Count9 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

2

latest Mar 31, 2026

Critical / warning

0 / 0

2 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

7

lapsed, stalled, closed

Latest event Stalled · Mar 31, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 2 filing events with values and deltas, latest 2026-03-31, and alerts on the next one
  • 7 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Saravana Kumar

Executive Officer, Director · Maple Grove, MN

Harley Handegard

Executive Officer · Maple Grove, MN

Katherine Kumar

Executive Officer · Maple Grove, MN

Jeffrey Chambers

Director · Maple Grove, MN

Buzz Benson

Director · Maple Grove, MN

Jonathan Chen

Director · Maple Grove, MN

Rhonda Robb

Director · Maple Grove, MN

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Piper Sandler & Co.CRD 665 on BrokerCheck

Minneapolis, MN · Soliciting in all states

Questions About 4C Medical Technologies, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is 4C Medical Technologies, Inc.?

4C Medical Technologies, Inc. is a Delaware corporation that filed a Form D with the SEC on March 31, 2026 in the Other Technology industry group. The filing claims Rule 506(b) for an offering of equity.

Is 4C Medical Technologies, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. 4C Medical Technologies, Inc. filed a Form D with the SEC on March 31, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $71,608,160 sold to 80 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is 4C Medical Technologies, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that 4C Medical Technologies, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has 4C Medical Technologies, Inc. raised?

4C Medical Technologies, Inc. reported $71,608,160 sold from 80 investors of a $166,095,595 total offering as of the Form D filed March 31, 2026. The filing states that the figure is combined across related vehicles, so it is not this entity's figure alone.

Who can invest in 4C Medical Technologies, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in 4C Medical Technologies, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling 4C Medical Technologies, Inc. and how are they paid?

The Form D names Piper Sandler & Co. (CRD 665) as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $9,295,063 and finders' fees as $0. Form D allows these to be estimates.

Who is behind 4C Medical Technologies, Inc.?

The Form D lists 7 related persons: Saravana Kumar, executive officer, director; Harley Handegard, executive officer; Katherine Kumar, executive officer; Jeffrey Chambers, director; Buzz Benson, director; Jonathan Chen, director; Rhonda Robb, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is 4C Medical Technologies, Inc. located?

The issuer's address on its SEC filings is 6655 Wedgwood Road North, Suite 160, Maple Grove, MN 55311. Its phone number of record is 952-334-4363. It is organized under the laws of Delaware.

How long is the 4C Medical Technologies, Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.

What is 4C Medical Technologies, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.